Techsomed Overview
Techsomed leverages generative AI to transform ablation therapy, a minimally invasive technique for treating tumors, heart arrhythmias, and chronic pain. The company’s first offering, the BioTraceIO360 software suite, focuses primarily on liver tumor ablation procedures. Leveraging standard medical imaging modalities such as Ultrasound, CT, and MRI, Techsomed empowers physicians with tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis. Techsomed secured FDA De-Novo clearance for its post-ablation tissue response prediction offering, positioning BioTrace as the first and only FDA-cleared solution of its kind. Complemented by a 510K clearance for ablation treatment planning and confirmation, these flagship products lay the foundation for the comprehensive BioTraceIO360 Solution. Operating globally, Techsomed maintains a subsidiary in Germany, housing an advanced R&D center—a spin-off from Fraunhofer, a leading German research institution specializing in imaging software solutions. Additionally, a subsidiary in Japan supports commercialization efforts in the Japanese and other Asian markets.
Cumulative Funding Raised Over Time ($)
—Jan 2018
$7.0MMar 2021
$9.6MMay 2019
Latest News
growth-positive
/PRNewswire/ -- Techsomed Ltd., a pioneering medical AI-powered software company specializing in image-guided therapy is pleased to announce a collaboration...
Techsomed Ltd., a medical AI-powered software company, has announced a pilot collaboration with Medtronic, a leader in healthcare technology. This partnership integrates Techsomeds BioTraceIO360™ software with Medtronics Emprint™ microwave ablation system to enhance image-guided ablation therapy. The collaboration aims to improve treatment precision by providing interventional radiologists with advanced capabilities for real-time visualization and predictive margin control. Techsomeds platform leverages generative AI to unify CT, MRI, and ultrasound data, enabling physicians to plan and validate treatments with greater accuracy. This partnership is expected to set a new standard in minimally invasive ablation treatment.
Partners
growth-positive
/PRNewswire/ -- Techsomed, a leader in AI-Driven Precision for Image-Guided Care, today announces U.S. FDA 510 (k) clearance expanding indications for...
Techsomed, a leader in AI-driven precision for image-guided care, has received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform, expanding its indications to include percutaneous ablation of soft tissue in the kidney. This clearance builds on its previous liver application approval, advancing Techsomeds vision for a multi-organ, hardware-agnostic image-guided therapy platform. The BioTraceIO360 platform offers planning, simulation, guidance, and verification for minimally invasive procedures, enhancing precision and consistency in interventional oncology. The software is now available in the U.S. for both liver and kidney ablation workflows, marking a significant milestone for the company.
FDA approved/pending approval
growth-positive
/PRNewswire/ -- Techsomed Ltd., a pioneering global medical software company, today announced the appointment of Robert (Bob) Gerberich as Chief Commercial...
Techsomed Ltd., a global medical software company, has appointed Robert (Bob) Gerberich as Chief Commercial Officer and Head of North America. Gerberich, with over 30 years of experience in the Medical Device, MedTech, and Diagnostics sectors, will lead global commercial functions and North America operations. Techsomed specializes in the AI-powered BioTraceIO™ software suite for Image-Guided Ablation Therapy, which includes FDA-cleared BioTraceIO™ Vision and BioTraceIO™ Precision. The appointment aims to accelerate the U.S. launch and global expansion of these innovative technologies, enhancing patient care and reducing costs in the healthcare market.
Management Changes
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $12.9M |
| Last funding | $2.5M |
| Stage | B |
| Rounds | 5 |
| Investors | 9 |
Team Members
11
Employees: 11-50
Web & Social Links
| Website | techsomed.com |
Locations
Derech Meir Weisgal 2, Rehovot, Israel
Photos & Videos
3 item(s)
Techsomed Business
Business models
B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareTags (21)
bioconvergencehospitalsimage-processingminimally-invasivemonitoringreal-timeimagingultrasoundmedical-devices3d-technologyoncologycardiologydoctorshealthcare-providersclinicsdiagnosticsblood-pressurecancerdigital-healthcaredecision-supportsoftware-platformGeographic Markets
JapanChinaAsiaTechsomed Financials
$12.9M
Total funding
Undisclosed
Capital raised
$2.5M
Last funding
B
Funding stage
5
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
—Jan 2018
$7.0MMar 2021
$9.6MMay 2019
Private Equity Funding
B Round
Mar 2021
$7M
Axil Capital (Lead)
,
NextLeap Ventures, Cobro Ventures, Radianx Capital, Johnson & Johnson Innovation, Magna Capital Partners, Yongjin Capital
A Round
May 2019
$2.6M
Johnson & Johnson Innovation (Lead)
,
Axil Capital, AMIT-Technion ( The Alfred Mann Institute), NextLeap Ventures, Screen Holdings
Seed
Jan 2018
Undisclosed
NextLeap Ventures
Non-Equity Funding
GrantEvent
Jan 2024
$2.5M
Israel Innovation Authority
GrantEvent
Dec 2015
$800K
Office of the Chief Scientist
Techsomed Lifecycle
Cumulative Funding Raised Over Time
—Jan 2018
$7.0MMar 2021
$9.6MMay 2019
All Events
B Round
Mar 2021
$7M
Axil Capital (Lead)
,
NextLeap Ventures, Cobro Ventures, Radianx Capital, Johnson & Johnson Innovation, Magna Capital Partners, Yongjin Capital
A Round
May 2019
$2.6M
Johnson & Johnson Innovation (Lead)
,
Axil Capital, AMIT-Technion ( The Alfred Mann Institute), NextLeap Ventures, Screen Holdings
Seed
Jan 2018
Undisclosed
NextLeap Ventures
GrantEvent
Jan 2024
$2.5M
Israel Innovation Authority
GrantEvent
Dec 2015
$800K
Office of the Chief Scientist
Techsomed News
11 articles
growth-positive
/PRNewswire/ -- Techsomed Ltd., a pioneering medical AI-powered software company specializing in image-guided therapy is pleased to announce a collaboration...
Techsomed Ltd., a medical AI-powered software company, has announced a pilot collaboration with Medtronic, a leader in healthcare technology. This partnership integrates Techsomeds BioTraceIO360™ software with Medtronics Emprint™ microwave ablation system to enhance image-guided ablation therapy. The collaboration aims to improve treatment precision by providing interventional radiologists with advanced capabilities for real-time visualization and predictive margin control. Techsomeds platform leverages generative AI to unify CT, MRI, and ultrasound data, enabling physicians to plan and validate treatments with greater accuracy. This partnership is expected to set a new standard in minimally invasive ablation treatment.
Partners
growth-positive
/PRNewswire/ -- Techsomed, a leader in AI-Driven Precision for Image-Guided Care, today announces U.S. FDA 510 (k) clearance expanding indications for...
Techsomed, a leader in AI-driven precision for image-guided care, has received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform, expanding its indications to include percutaneous ablation of soft tissue in the kidney. This clearance builds on its previous liver application approval, advancing Techsomeds vision for a multi-organ, hardware-agnostic image-guided therapy platform. The BioTraceIO360 platform offers planning, simulation, guidance, and verification for minimally invasive procedures, enhancing precision and consistency in interventional oncology. The software is now available in the U.S. for both liver and kidney ablation workflows, marking a significant milestone for the company.
FDA approved/pending approval
growth-positive
/PRNewswire/ -- Techsomed Ltd., a pioneering global medical software company, today announced the appointment of Robert (Bob) Gerberich as Chief Commercial...
Techsomed Ltd., a global medical software company, has appointed Robert (Bob) Gerberich as Chief Commercial Officer and Head of North America. Gerberich, with over 30 years of experience in the Medical Device, MedTech, and Diagnostics sectors, will lead global commercial functions and North America operations. Techsomed specializes in the AI-powered BioTraceIO™ software suite for Image-Guided Ablation Therapy, which includes FDA-cleared BioTraceIO™ Vision and BioTraceIO™ Precision. The appointment aims to accelerate the U.S. launch and global expansion of these innovative technologies, enhancing patient care and reducing costs in the healthcare market.
Management Changes
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
Techsomed Announces Field Evaluation of its image guided ablation therapy software using GE HealthCare LOGIQ™ ultrasound systems at top US clinical sites
TechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS, to accelerate End-to-End Solution for Image-Guided Tumor Ablation Therapy
TechsoMed Completes Enrollment in United States Pivotal Trial of BioTraceIO Software for Liver Ablation Outcomes Assessment - Endovascular Today
The Japanese subsidiary of TechsoMed Ltd., an Israeli company that develops ultrasound based image analysis software system for tissue damage monitoring and control in multi-clinical applications, steadily expands its business | 2022 - Events & News - Investing in Japan - Japan External Trade Organization
growth-positive
TechsoMed Raises $7 Million Series B financing led by Axil Capital
TechsoMed, a developer of AI and Algorithm powered real-time tissue damage imaging technology, has closed a US$7 million Series B equity financing round. The funding round was led by Axil Capital and included participation from Yongjin Capital, Cobro Ventures, Magna Capital Partners, and Radianx Capital, as well as existing investors Johnson & Johnson Innovation – JJDC, Inc. and NextLeap Ventures. The companys technology, called BioTrace, has the potential to help physicians ensure treatment accuracy and increase treatment efficacy. By tracing the tissues biological response, BioTrace provides a unique damage map that represents the full extent of damage as seen 24 hours post-treatment. TechsoMed is collaborating with medical centers worldwide to secure regulatory approval for its BioTrace system in liver tumor ablation and is also developing the system for cardiac and pain ablation procedures.
Investment
growth-positive
Thermal ablation treatment co Techsomed raises $2.6m
Israeli thermal ablation treatment company Techsomed has raised $2.6 million in a financing round led by Johnson & Johnson Innovation. The funds will be used for further development of its BioTrace image analysis system for predicting post-treatment ablation morphology in real time. The system aims to enhance the surgeons level of control and accuracy during thermal ablation procedures, minimizing healthy tissue damage and maximizing target tissue ablation. The financing round demonstrates confidence in Techsomeds technology and its potential to make thermal ablation safer and more effective.
Investment
Techsomed Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 29 |
| Team members | 11 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Techsomed Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514804343 |
| Crunchbase | techsomed |
| Phone | +97286198866 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-03-03T00:00:00.000Z |
| Created | 2014-07-16T00:00:00.000Z |
| Claimed | Yes |